Once a drug is a big hit, they are always looking to make it a bigger hit.
Headline Medscape News April 2024
Semaglutide Improves Knee Osteoarthritis Pain, Physical Function in Phase 3 Trial
The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy) not only induced weight loss but also improved knee pain in people with knee osteoarthritis (OA) and obesity, according to results from the STEP 9 study reported at th…